ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
소토라십정 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 17억 1,000만 달러로 평가되었고, 2025년에는 19억 2,000만 달러에 달하고, CAGR 12.5%로 성장할 전망입니다. 실적기간의 성장은 비소세포폐암의 유병률 증가, 표적암 치료에 대한 의식 증가, 정밀의료 채택 확대, 암치료센터 확대, 항암제에 대한 정부지원 증가로 이어졌습니다.
소토라십정 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 12.1%로 30억 4,000만 달러로 성장할 전망입니다. 예측기간의 성장은 KRAS 억제제 조사에 대한 투자 증가, 소트라시브 제조능력 확대, 바이오테크놀러지 기업과 제약 기업간의 제휴 증가, 개별화 암 치료에 대한 수요 증가, 경구 표적 요법의 채택 확대 등이 뒷받침될 것으로 보입니다. 예측기간 중에 예상되는 주요 동향으로는 표적 치료제 개발의 진전, KRAS 변이 검출법의 개선, 암 치료제에 대한 연구개발 투자 증가, 경구암 제제의 혁신, 지속 가능한 의약품 제조 방법의 진보 등이 있습니다.
암의 유병률 증가는 앞으로 수년간 소토라십정 시장의 성장을 가속할 것으로 예측됩니다. 암은 통제 불가능한 비정상 세포의 증식을 특징으로 하는 질환군으로 구성되어, 주변 조직에 침윤하여 신체의 다른 부위로 전이할 가능성이 있습니다. 이러한 유병률의 상승은 인구의 고령화가 주된 원인이며, 고령자는 다양한 형태의 암을 발병할 위험이 현저히 높고, 사례의 대부분은 65세 이상에서 발생하고 있습니다. 소토라십정의 기능은 KRAS G12C 돌연변이를 선택적이고 비가역적으로 표적화함으로써 돌연변이 단백질을 효과적으로 불활성 상태로 잠그고 진행된 고형암, 특히 비소세포 폐암의 경우에서 볼 수 있는 제어 불가능한 세포 증식을 방지하는 것입니다. 예를 들어 2024년 2월 스위스에 본부를 둔 공중위생을 전문으로 하는 국제기구인 세계보건기구(WHO)는 2050년까지 새롭게 발생하는 암 환자는 3,500만명을 넘을 것으로 예측되며, 2022년 추정 2,000만명에서 77% 증가할 것으로 보고했습니다. 이 때문에 암 부담의 증대가 소토라십정 시장의 확대에 기여하고 있습니다.
소토라십정 시장에서 사업을 전개하는 주요 기업은 치료 성적 개선과 치료 저항성 극복을 목표로 병용 요법을 진행하고 있습니다. 병용요법은 복수의 메커니즘으로 암을 공격하기 위해 2유형 이상의 약제를 병용하는 것입니다. 이 접근법은 치료 효과를 높이고, 내성을 늦추거나 극복하고, 재발 가능성을 줄이고, 환자의 QOL을 향상시킵니다. 예를 들어, 2025년 1월 미국 바이오테크놀러지 기업인 암젠사는 표준 화학요법을 받은 적이 있는 KRAS G12C 유전자 변이를 가진 전이성 대장암 성인 환자에 대한 소트라시브와 파니투무맙의 병용 요법에 대해 미국 식품의약국에서 승인을 받았습니다. 이번 승인은 3상 CodeBreaK 300 시험의 결과를 받은 것으로, 이 병용 요법은 시험 담당 의사가 선택한 표준 치료에 비해 무증악 생존 기간을 2배 이상 연장하는 것으로 나타났습니다. 소트라시브는 KRAS G12C 돌연변이에 대한 최초의 경구 억제제이며, 불활성형 돌연변이 KRAS 단백질에 선택적으로 결합함으로써 기능하며, 종양의 성장을 멈추고 암 관련 신호전달 경로를 차단합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 소토라십정 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계 소토라십정 시장 : 성장률 분석
세계 소토라십정 시장 실적 : 규모와 성장, 2019년-2024년
세계 소토라십정 시장 예측 : 규모와 성장, 2024년-2029년, 2034년
세계 소토라십정 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 소토라십정 시장 : 제형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
40밀리그램(Mg) 정제
120밀리그램(Mg) 정제
240밀리그램(Mg) 정제
기타 제형
세계의 소토라십정 시장 : 환자 속성별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
청소년
성인
고령자
세계의 소토라십정 시장 : 유통 채널별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 소토라십정 시장 : 용도별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
비소세포 폐암
대장암
기타 용도
세계의 소토라십정 시장 : 최종사용자별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
병원
종양센터
클리닉
기타 최종 사용자
제7장 지역별/국가별 분석
세계의 소토라십정 시장 : 지역별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
세계의 소토라십정 시장 : 국가별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
소토라십정 시장 : 경쟁 구도
소토라십정 시장 : 기업 프로파일
Amgen Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Ziska Pharmaceuticals Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Everest Pharmaceuticals Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Lucius Pharmaceutical Co. Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 세계 시장 경쟁 벤치마킹과 대시보드
제32장 주요 인수합병(M&A)
제33장 최근 시장 동향
제34장 시장의 잠재력이 높은 국가, 부문, 전략
소토라십정 시장 2029년 : 새로운 기회를 제공하는 국가
소토라십정 시장 2029년 : 새로운 기회를 제공하는 부문
소토라십정 시장 2029년 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제35장 부록
SHW
영문 목차
영문목차
Sotorasib tablets are a prescription medicine developed for treating certain cases of non-small cell lung cancer in patients whose tumors carry the KRAS G12C gene mutation. The drug binds to the abnormal KRAS protein, preventing it from transmitting signals that drive uncontrolled cancer cell growth and survival. This targeted inhibition can reduce tumor activity, slow disease progression, and improve treatment outcomes in patients with limited options from standard therapies.
The primary dosage forms of sotorasib tablets include 40 mg, 120 mg, 240 mg, and other strengths. The 40 mg tablets provide a lower-strength option for precise dose adjustments to enhance safety and tolerability. Sotorasib is used across patient populations including adolescents, adults, and seniors. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others. Key applications include non-small cell lung cancer, colorectal cancer, and additional indications, with end-users comprising hospitals, oncology centers, clinics, and other healthcare providers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The sotorasib tablets market research report is one of a series of new reports from The Business Research Company that provides sotorasib tablets market statistics, including sotorasib tablets industry global market size, regional shares, competitors with the sotorasib tablets market share, sotorasib tablets market segments, market trends, and opportunities, and any further data you may need to thrive in the sotorasib tablets industry. This sotorasib tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sotorasib tablets market size has grown rapidly in recent years. It will grow from $1.71 billion in 2024 to $1.92 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. Growth in the historic period was driven by the increasing prevalence of non-small cell lung cancer, rising awareness of targeted cancer therapies, growing adoption of precision medicine, expansion of oncology treatment centers, and increasing government support for cancer drugs.
The sotorasib tablets market size is expected to see rapid growth in the next few years. It will grow to $3.04 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. Growth in the forecast period is expected to be supported by rising investment in KRAS inhibitor research, expansion of sotorasib manufacturing capacity, increasing collaborations between biotech and pharmaceutical companies, growing demand for personalized cancer treatment, and wider adoption of oral targeted therapies. Key trends anticipated for the forecast period include advancements in targeted therapy development, improvements in KRAS mutation detection methods, increased R&D investment in oncology drugs, innovation in oral cancer formulations, and progress in sustainable drug manufacturing practices.
The increasing prevalence of cancer is expected to drive the growth of the sotorasib tablets market in the coming years. Cancer consists of a group of diseases characterized by the uncontrolled growth of abnormal cells that invade surrounding tissues and may spread to other parts of the body. This rising prevalence is largely attributed to an aging population, as older individuals are at significantly higher risk for developing various forms of cancer, with the majority of cases occurring in people over the age of 65. Sotorasib tablets function by selectively and irreversibly targeting the KRAS G12C mutation, effectively locking the mutated protein in an inactive state to prevent the uncontrolled cell growth seen in advanced solid tumors, particularly in cases of non-small cell lung cancer. For example, in February 2024, the World Health Organization, an international organization based in Switzerland focused on public health, reported that over 35 million new cancer cases are projected by 2050, representing a 77 percent increase from the estimated 20 million cases in 2022. Therefore, the growing cancer burden is contributing to the expansion of the sotorasib tablets market.
Key companies operating in the sotorasib tablets market are advancing combination therapies to improve outcomes and overcome treatment resistance. Combination therapies involve the use of two or more drugs that work together to attack cancer through multiple mechanisms. This approach enhances treatment efficacy, delays or overcomes resistance, reduces the chances of recurrence, and improves patient quality of life. For instance, in January 2025, Amgen Inc., a biotechnology company based in the United States, received approval from the United States Food and Drug Administration for the use of sotorasib in combination with panitumumab for adult patients with metastatic colorectal cancer carrying the KRAS G12C mutation who had previously undergone standard chemotherapy. This approval followed the results of the Phase 3 CodeBreaK 300 study, which showed that the combination more than doubled progression-free survival compared to the standard-of-care treatment chosen by investigators. Sotorasib is the first oral inhibitor of the KRAS G12C mutation, functioning by selectively binding to the mutant KRAS protein in its inactive form to halt tumor growth and block cancer-related signaling pathways.
In October 2022, BridgeBio Pharma, a biopharmaceutical company based in the United States with a focus on genetic diseases and cancer, entered into a partnership with Amgen to assess the combination of BBP-398 and Lumakras in patients with non-small cell lung cancer harboring the KRAS G12C mutation. The goal of this partnership is to explore a potentially more effective therapeutic approach for these patients, addressing the significant unmet needs associated with this specific mutation. Amgen is a biopharmaceutical company in the United States that develops therapies for serious illnesses, including sotorasib, a treatment for cancers involving KRAS G12C mutations.
Major players in the sotorasib tablets market are Amgen Inc., Ziska Pharmaceuticals Limited, Everest Pharmaceuticals Inc., Lucius Pharmaceutical Co. Ltd.
North America was the largest region in the sotorasib tablets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sotorasib tablets report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sotorasib tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The sotorasib tablets market consists of sales of lumakras, lumykras, and diagnostic companion kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sotorasib Tablets Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on sotorasib tablets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for sotorasib tablets ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sotorasib tablets market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Dosage Form: 40 Milligrams (Mg) Tablets; 120 Milligrams (Mg) Tablets; 240 Milligrams (Mg) Tablets; Other Dosage Forms
2) By Patient Demographics: Adolescents; Adult; Senior Adults
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By Application: Non-Small Cell Lung Cancer; Colorectal Cancer; Other Applications
5) By End-User: Hospitals; Oncology Centers; Clinics; Other End-Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Sotorasib Tablets Market Characteristics
3. Sotorasib Tablets Market Trends And Strategies
4. Sotorasib Tablets Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Sotorasib Tablets Growth Analysis And Strategic Analysis Framework
5.1. Global Sotorasib Tablets PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Sotorasib Tablets Market Growth Rate Analysis
5.4. Global Sotorasib Tablets Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Sotorasib Tablets Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Sotorasib Tablets Total Addressable Market (TAM)
6. Sotorasib Tablets Market Segmentation
6.1. Global Sotorasib Tablets Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
40 Milligrams (Mg) Tablets
120 Milligrams (Mg) Tablets
240 Milligrams (Mg) Tablets
Other Dosage Forms
6.2. Global Sotorasib Tablets Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adolescents
Adult
Senior Adults
6.3. Global Sotorasib Tablets Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Sotorasib Tablets Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Small Cell Lung Cancer
Colorectal Cancer
Other Applications
6.5. Global Sotorasib Tablets Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Oncology Centers
Clinics
Other End-Users
7. Sotorasib Tablets Market Regional And Country Analysis
7.1. Global Sotorasib Tablets Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Sotorasib Tablets Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
